Cannabis pharmaceuticals are set to explode into a multi‑billion‑dollar industry, with the market projected to hit $111.1 billion by 2032.
Market Overview and Forecast
The global cannabis pharmaceuticals market was valued at $4.7 billion in 2025 and is expected to reach $111.1 billion in 2032, growing at a 57.1% compound annual growth rate, according to the “Cannabis Pharmaceuticals – Global Strategic Business Report” added to ResearchAndMarkets.com.
North America leads with a $1.4 billion 2025 valuation, while China is forecast to expand at a 54.1% CAGR, reaching $17.5 billion by 2032, the report states.
Key Growth Drivers
Legalization of medical cannabis worldwide fuels expanding research and development, while regulatory approvals in the United States and Europe legitimize the sector for pharmaceutical companies.
The opioid crisis has spurred demand for non‑addictive pain relief, positioning cannabis‑based drugs as a preferred alternative for chronic pain, cancer and arthritis patients.
Advances in formulation science, including improved bioavailability, stability and targeted delivery, further accelerate market momentum.
Therapeutic Areas Driving Demand
Chronic pain, neurological disorders and mental health conditions generate the strongest demand, with FDA‑approved drugs such as Epidiolex for epilepsy and Sativex for multiple sclerosis spasticity leading the way.
Growing acceptance of cannabis for pain management is reshaping prescribing practices and expanding the patient base beyond traditional specialties.
Expert Insights and Report Features
ResearchAndMarkets.com compiled insights from 43 domain experts across enterprise, academia, industry and government, delivering comprehensive intelligence on market dynamics.
The report offers independent sales data, regional breakdowns for the U.S., China, Europe, Asia‑Pacific and other regions, and profiles of key players including AbbVie Inc., Aphria Inc., Aurora Cannabis Inc., Canopy Growth Corporation and others.
Clients receive a year of complimentary updates, ensuring they stay current with the latest market developments.
Regional and Segment Highlights
The Sativex brand is projected to reach $82.5 billion by 2032, driven by a 62% CAGR, while the Epidiolex brand is expected to grow at a 51% CAGR, according to the report’s segment analysis.
These figures underscore the rapid expansion of cannabinoid‑based therapies across global healthcare systems.
